Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05750589

Sterilizing Eye Solution to Improve Patient Comfort

Conditions: Retinal Disease

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: 1
Phase: PHASE3
Enrollment: 240
Sponsor: iRenix Medical, Inc.

Summary

This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.

Eligibility Criteria

Inclusion Criteria:Capable of giving informed consentStated willingness to comply with all study procedures and availability for the duration of the studyMale or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyesExclusion Criteria:Current or past diagnosis of endophthalmitisCurrent diagnosis of uveitisMonocular patients (vision 20/100 or worse in one eye) who are receiving injections in the better seeing eyeCurrent use of viscous lidocaine products for ocular anesthesia prior to IVTCurrently receiving intravitreal steroid injectionsConcurrent participation in another clinical trialFemales who are pregnant, planning to become pregnant or lactating

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05750589). StuddyBuddy aggregates publicly available trial information.